Cover Image
市場調查報告書

慢性腎臟病造成之貧血 (腎性貧血):開發中產品分析

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363106
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
慢性腎臟病造成之貧血 (腎性貧血):開發中產品分析 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 136 Pages
簡介

本報告提供慢性腎臟病造成之貧血 (腎性貧血) 治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

慢性腎臟病造成之貧血 (腎性貧血)概要

治療藥的開發

  • 開發中產品的概要

慢性腎臟病造成之貧血 (腎性貧血):企業開發中的治療藥

慢性腎臟病造成之貧血 (腎性貧血):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

慢性腎臟病造成之貧血 (腎性貧血):企業開發中的產品

慢性腎臟病造成之貧血 (腎性貧血)治療藥的開發企業

  • 3SBio Inc.
  • Acceleron Pharma, Inc.
  • Akebia Therapeutics, Inc.
  • Amgen Inc.
  • Bayer AG
  • BIOCAD
  • CCM Duopharma Biotech Bhd.
  • Chong Kun Dang Pharmaceutical Corp.
  • CJ HealthCare Corp.
  • 第一三共
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Ltd.
  • 日本煙草產業
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • LG Life Science LTD.
  • Medgenics, Inc.
  • Myungmoon pharmaceutical Co., Ltd.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Pieris Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Zydus Cadila Healthcare Limited

慢性腎臟病造成之貧血 (腎性貧血):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

慢性腎臟病造成之貧血 (腎性貧血):暫停中的計劃

慢性腎臟病造成之貧血 (腎性貧血):中止開發的產品

慢性腎臟病造成之貧血 (腎性貧血):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8849IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease - Pipeline Review, H2 2016, provides an overview of the Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 9, 4, 1, 6, 2 and 1 respectively.

Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anemia in Chronic Kidney Disease (Renal Anemia) Overview
  • Therapeutics Development
    • Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia) - Overview
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics under Development by Companies
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Products under Development by Companies
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Acceleron Pharma Inc
    • Aevi Genomic Medicine Inc
    • Akebia Therapeutics Inc
    • Amgen Inc
    • Bayer AG
    • Biocad
    • CCM Duopharma Biotech Bhd
    • Chong Kun Dang Pharmaceutical Corp
    • CJ HealthCare Corp
    • Daiichi Sankyo Company Ltd
    • Dong-A Socio Holdings Co Ltd
    • Dr. Reddy's Laboratories Ltd
    • FibroGen Inc
    • GlaxoSmithKline Plc
    • Intas Pharmaceuticals Ltd
    • Japan Tobacco Inc
    • JCR Pharmaceuticals Co Ltd
    • Jiangsu Hansoh Pharmaceutical Co Ltd
    • LG Life Science LTD
    • Myungmoon pharmaceutical Co Ltd
    • Panacea Biotec Ltd
    • Pfizer Inc
    • PharmaEssentia Corp
    • PhytoHealth Corp
    • Pieris Pharmaceuticals Inc
    • Reliance Life Sciences Pvt Ltd
    • Sandoz International GmbH
    • Zydus Cadila Healthcare Ltd
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • daprodustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-1093 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPO-018B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin zeta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erythropoietin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FG-2216 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSA-EPO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JTZ-951 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBDE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDGN-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMP-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molidustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEG-EPO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peg-EPO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEG-EPO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegylated erythropoietin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHEP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRS-080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Renal Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • roxadustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotatercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSS-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSS-17 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vadadustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease
      • Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia
      • Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
      • Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients
      • Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131)
      • Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease
      • Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan
      • Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
      • May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
      • May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat
      • Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings
      • Apr 08, 2016: Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's nephrology indication
      • Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat
      • Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat's Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease
      • Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Acceleron Pharma Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by LG Life Science LTD, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Sandoz International GmbH, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H2 2016
  • Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top